ZLDPF Quote, Financials, Valuation and Earnings

Structure Therapeutics has a net margin of -3213.72% compared to Zealand Pharma AS's net margin of --. Zealand Pharma AS's return on equity of -17.27% beat Structure Therapeutics's return on equity of --.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -70.43%. On the other hand Structure Therapeutics has an analysts' consensus of $80.15 which suggests that it could grow by 363.05%. Given that Structure Therapeutics has higher upside potential than Zealand Pharma AS, analysts believe Structure Therapeutics is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.923, which suggesting that the stock is 7.706% less volatile than S&P 500. In comparison Structure Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Structure Therapeutics pays out -- of its earnings as a dividend.

Zealand Pharma AS quarterly revenues are $1.3M, which are larger than Structure Therapeutics quarterly revenues of --. Zealand Pharma AS's net income of -$41.6M is lower than Structure Therapeutics's net income of -$36.5M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Structure Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 557.42x versus -- for Structure Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -3213.72% compared to Zealand Pharma AS's net margin of 32.59%. Zealand Pharma AS's return on equity of -17.27% beat Eli Lilly and's return on equity of 80.24%.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -70.43%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.35%. Given that Eli Lilly and has higher upside potential than Zealand Pharma AS, analysts believe Eli Lilly and is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.923, which suggesting that the stock is 7.706% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zealand Pharma AS quarterly revenues are $1.3M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Zealand Pharma AS's net income of -$41.6M is lower than Eli Lilly and's net income of $4.4B. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 70.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 557.42x versus 16.58x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -3213.72% compared to Zealand Pharma AS's net margin of 32.95%. Zealand Pharma AS's return on equity of -17.27% beat Novo Nordisk AS's return on equity of 86.85%.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -70.43%. On the other hand Novo Nordisk AS has an analysts' consensus of $107.12 which suggests that it could grow by 54.26%. Given that Novo Nordisk AS has higher upside potential than Zealand Pharma AS, analysts believe Novo Nordisk AS is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.923, which suggesting that the stock is 7.706% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.645%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.33% to investors and pays a quarterly dividend of $1.10 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zealand Pharma AS quarterly revenues are $1.3M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Zealand Pharma AS's net income of -$41.6M is lower than Novo Nordisk AS's net income of $4B. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 21.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 557.42x versus 7.36x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -3213.72% compared to Zealand Pharma AS's net margin of --. Zealand Pharma AS's return on equity of -17.27% beat Viking Therapeutics's return on equity of --.

Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -70.43%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 287.11%. Given that Viking Therapeutics has higher upside potential than Zealand Pharma AS, analysts believe Viking Therapeutics is more attractive than Zealand Pharma AS.

Zealand Pharma AS has a beta of 0.923, which suggesting that the stock is 7.706% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Zealand Pharma AS quarterly revenues are $1.3M, which are larger than Viking Therapeutics quarterly revenues of --. Zealand Pharma AS's net income of -$41.6M is lower than Viking Therapeutics's net income of -$35.4M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 557.42x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.